Company Description
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.
Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
| Country | United States |
| IPO Date | Mar 1, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Dr. Stacy R. Lindborg Ph.D. |
Contact Details
Address: 997 Lenox Drive Lawrenceville, New Jersey United States | |
| Website | https://www.imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| CUSIP Number | n/a |
| ISIN Number | US15117N6022 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stacy R. Lindborg Ph.D. | President, Chief Executive Officer & Director |
| David G. Gaiero CPA | Chief Financial Officer & Corporate Secretary |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Executive Vice President & Chief Scientific Officer |
| Michael H. Tardugno | Executive Chairman |
| Susan Mary Eylward | General Counsel & Corporate Secretary |
| Timothy J. Tumminello CPA | Chief Accounting Officer & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 4/A | [Amend] Filing |
| Oct 08, 2024 | 4 | Filing |
| Oct 07, 2024 | 3 | Filing |
| Oct 07, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 424B3 | Filing |